To provide the information your oncologist is not telling you or doesn't have the time to!
Dive into the heart of innovation with our “Clinical Trials” subcategory, where we unveil the dynamic world of oncology research in real-time. Discover the latest developments and breakthroughs in cancer treatment as we explore ongoing clinical trials and their potential impact on patient care. Gain insights into the rigorous process of testing novel therapies, uncover promising treatment options, and learn how these trials contribute to advancing the field of oncology. Stay informed and be part of the journey towards more effective and compassionate cancer care.
Bladder cancer, particularly muscle-invasive bladder cancer (MIBC), poses significant treatment challenges due to its high recurrence rate and aggressive nature. Traditionally, neoadjuvant chemotherapy followed by surgery (radical cystectomy) has been the standard of care for cisplatin-eligible patients. However, researchers have been exploring ways to improve outcomes by incorporating immunotherapy into treatment. A recent phase 3 …
IgG4-related disease (IgG4-RD) is a chronic, immune-mediated disorder that can affect multiple organs, causing inflammation, fibrosis, and long-term organ damage. I uncommonly see these patients as they often present as a retroperitoneal mass concerning for a connective tissue malignancy however biopsied proven IgG4 related non-malignant disease requiring immunosuppressant treatment which I often did as there …
For patients with a specific type of breast cancer—hormone receptor-positive, HER2-negative—that also carries a PIK3CA mutation, a new combination treatment shows promising results. The treatment combines inavolisib, a targeted therapy, with palbociclib and fulvestrant, helping to significantly slow disease progression compared to standard treatment. This combination not only targets multiple cancer growth pathways but also …
Anaplastic thyroid carcinoma (ATC) is one of the most aggressive and challenging types of thyroid cancer. Known for its rapid growth, resistance to conventional therapies, and poor prognosis, ATC has historically had limited treatment options. However, recent studies, including groundbreaking research by Dr. Maria Cabanillas and colleagues at MD Anderson Cancer Center, have highlighted the …
In the world of oncology, chimeric antigen receptor (CAR) T-cell therapy has revolutionized the treatment of certain B-cell malignancies like lymphomas and leukemias. But a recent study in The New England Journal of Medicine has opened the door to an entirely new application: using CAR T-cell therapy to treat severe autoimmune diseases such as systemic lupus erythematosus …
Multiple myeloma (MM) is a type of blood cancer originating in the plasma cells of the bone marrow, leading to an overproduction of abnormal plasma cells. This accumulation disrupts normal blood cell production and results in a range of complications, such as bone pain, anemia, kidney issues, and increased infection risk. Historically, treatment options for …
Prostate cancer continues to pose a significant challenge for both patients and healthcare providers. In the realm of radiation therapy, the development of advanced techniques has transformed the landscape of treatment. A recent phase 3 trial comparing Stereotactic Body Radiotherapy (SBRT) to conventional radiotherapy for intermediate-risk prostate cancer provides new insights into how we can deliver effective …
The treatment landscape for advanced-stage classic Hodgkin’s lymphoma (cHL) is rapidly evolving. Traditionally, chemotherapy regimens such as AVD (doxorubicin, vinblastine, dacarbazine) or combinations including brentuximab vedotin have been used to manage this challenging disease. However, a groundbreaking phase 3 clinical trial (S1826) has introduced a promising new regimen—nivolumab (N+AVD)—that is proving to be superior in …
A new article published in the NEJM showing impressive efficacy in NSCLC, here’s the summary below. The landscape of non-small cell lung cancer (NSCLC) treatment continues to evolve, particularly for patients with EGFR mutations. Historically, EGFR tyrosine kinase inhibitors (TKIs) like osimertinib have been the first line of defense, providing improved progression-free survival for patients. …
Immunotherapy has made significant strides in cancer treatment, but microsatellite stable (MSS) metastatic colorectal cancer (mCRC) has long posed a challenge due to its resistance to immune-based therapies. However, promising results from a recent phase 2/3 trial have shown that the individualized neoantigen-directed immunotherapy, GRANITE, may change the outlook for patients with MSS mCRC. This innovative therapy, combined …